Sonoma Pharmaceuticals (SNOA) Interest & Investment Income (2010 - 2021)
Sonoma Pharmaceuticals' (SNOA) quarterly Interest & Investment Income came in at $2000.0 in Q1 2021, up 102.99% year-on-year from $985.29 in Q1 2020, and down 33.33% quarter-over-quarter from $3000.0 in Q4 2020.
Sonoma Pharmaceuticals (SNOA) Interest & Investment Income (2010 - 2021) Analysis & Trends
Sonoma Pharmaceuticals' Interest & Investment Income history runs 12 years deep, the most recent figure standing at $2000.0 for Q1 2021.
- On a quarterly basis, Interest & Investment Income rose 102.99% year-over-year to $2000.0 in Q1 2021; TTM through Mar 2021 was $15000.0, a 70.0% decrease from a year earlier, with the FY2021 full-year figure at $16000.0, down 68.0% from the prior year.
- Interest & Investment Income eased to $2000.0 in Q1 2021 per SNOA's latest filing, from $3000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $173000.0 in Q1 2018 and bottomed at -$67000.0 in Q1 2020.
- The 5-year median for Interest & Investment Income is $33000.0 (2019), against an average of $31000.0.
- Across the five-year window, Interest & Investment Income jumped 5200.0% in 2017 and slumped 231.37% in 2020, its largest moves.
- Year by year, Interest & Investment Income stood at $14000.0 in 2017, then soared by 164.29% to $37000.0 in 2018, then retreated by 10.81% to $33000.0 in 2019, then plunged by 90.91% to $3000.0 in 2020, then tumbled by 33.33% to $2000.0 in 2021.
- Per Business Quant, the three latest SNOA Interest & Investment Income figures stand at $2000.0 (Q1 2021), $3000.0 (Q4 2020), and $8000.0 (Q3 2020).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Sonoma Pharmaceuticals | 1.95 Mn | -445,560.06 | 2.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 2,000.00 |
| Dec 31, 2020 | 3,000.00 |
| Sep 30, 2020 | 8,000.00 |
| Jun 30, 2020 | 2,000.00 |
| Mar 31, 2020 | -67,000.00 |
| Dec 31, 2019 | 33,000.00 |
| Sep 30, 2019 | 42,000.00 |
| Jun 30, 2019 | 42,000.00 |
| Mar 31, 2019 | 51,000.00 |
| Dec 31, 2018 | 37,000.00 |
| Sep 30, 2018 | 47,000.00 |
| Jun 30, 2018 | 55,000.00 |
| Mar 31, 2018 | 173,000.00 |
| Dec 31, 2017 | 14,000.00 |
| Sep 30, 2017 | 18,000.00 |
| Jun 30, 2017 | 53,000.00 |
| Mar 31, 2017 | 14,000.00 |
| Dec 31, 2016 | 6,000.00 |
| Sep 30, 2016 | 1,000.00 |
| Jun 30, 2016 | 1,000.00 |